166 related articles for article (PubMed ID: 35218398)
1. Polatuzumab vedotin combined with rituximab-bendamustine immediately before stem cell mobilization in relapsed diffuse large B-cell lymphoma.
Takakuwa T; Okayama Y; Nakamae H; Kuno M; Makuuchi Y; Harada N; Okamura H; Nishimoto M; Nakashima Y; Koh H; Hino M
Ann Hematol; 2022 Jul; 101(7):1609-1610. PubMed ID: 35218398
[No Abstract] [Full Text] [Related]
2. Polatuzumab vedotin to treat relapsed or refractory diffuse large B-cell lymphoma, in combination with bendamustine plus rituximab.
Amaya ML; Jimeno A; Kamdar M
Drugs Today (Barc); 2020 Apr; 56(4):287-294. PubMed ID: 32309823
[TBL] [Abstract][Full Text] [Related]
3. Polatuzumab vedotin plus bendamustine and rituximab (Pola-BR) was effective for neurolymphomatosis in a patient with refractory diffuse large B-cell lymphoma.
Shinmura K; Okubo S; Kadota S; Nakayama H; Sakurai A; Kurosawa S; Ito C; Aisa Y; Nakazato T
Ann Hematol; 2023 Jan; 102(1):223-225. PubMed ID: 36394579
[No Abstract] [Full Text] [Related]
4. United we stand: Double targeting of CD79B and CD20 in diffuse large B-cell lymphoma.
Tarantelli C; Bertoni F
Br J Haematol; 2022 Oct; 199(2):169-170. PubMed ID: 35917107
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy and safety of Polatuzumab Vedotin in combination with rituximab plus bendamustine in patients with relapsed/refractory diffuse large B-cell lymphoma: a single center analysis].
Kong FC; Yu M; Zhou YL; Wang SX; Li F
Zhonghua Xue Ye Xue Za Zhi; 2022 Jan; 43(1):66-69. PubMed ID: 35231996
[No Abstract] [Full Text] [Related]
6. [Polatuzumab vedotin, bendamustine, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma, including the outcome as a bridging treatment to CAR-T cell therapy or allogeneic hematopoietic stem cell transplant].
Morita Y; Yagi Y; Kanemasa Y; Sasaki Y; Ishimine K; Hayashi Y; Mino M; Ohigashi A; Tamura T; Nakamura S; Okuya T; Shimizuguchi T; Shingai N; Toya T; Shimizu H; Najima Y; Kobayashi T; Haraguchi K; Doki N; Okuyama Y; Ohashi K; Shimoyama T
Rinsho Ketsueki; 2023; 64(7):586-595. PubMed ID: 37544717
[TBL] [Abstract][Full Text] [Related]
7. Poor clinical outcome of relapsed/refractory diffuse large B-cell lymphoma with MYC translocation treated with polatuzumab vedotin, bendamustine, and rituximab.
Saburi M; Sakata M; Kodama Y; Uraisami K; Takata H; Miyazaki Y; Wada J; Urabe S; Ohtsuka E
J Clin Exp Hematop; 2023 Sep; 63(3):201-204. PubMed ID: 37518271
[No Abstract] [Full Text] [Related]
8. Tafasitamab Plus Lenalidomide Versus 3 Rituximab-Based Treatments for Non-Transplant Eligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Matching-Adjusted Indirect Comparison.
Cordoba R; Prawitz T; Westley T; Sharma A; Ambarkhane S; Kapetanakis V; Sabatelli L
Adv Ther; 2022 Jun; 39(6):2668-2687. PubMed ID: 35403948
[TBL] [Abstract][Full Text] [Related]
9. Refractory hemophagocytic lymphohistiocytosis secondary to polatuzumab vedotin plus rituximab and bendamustine.
Lv K; Kong F; Yu M; Zhou Y; Li F
Ann Hematol; 2024 Mar; 103(3):1017-1019. PubMed ID: 38155243
[No Abstract] [Full Text] [Related]
10. A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B-cell lymphoma.
Terui Y; Rai S; Izutsu K; Yamaguchi M; Takizawa J; Kuroda J; Ishikawa T; Kato K; Suehiro Y; Fukuhara N; Ohmine K; Goto H; Yamamoto K; Kanemura N; Ueda Y; Ishizawa K; Kumagai K; Kawasaki A; Saito T; Hashizume M; Shibayama H
Cancer Sci; 2021 Jul; 112(7):2845-2854. PubMed ID: 33942442
[TBL] [Abstract][Full Text] [Related]
11. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Sehn LH; Herrera AF; Flowers CR; Kamdar MK; McMillan A; Hertzberg M; Assouline S; Kim TM; Kim WS; Ozcan M; Hirata J; Penuel E; Paulson JN; Cheng J; Ku G; Matasar MJ
J Clin Oncol; 2020 Jan; 38(2):155-165. PubMed ID: 31693429
[TBL] [Abstract][Full Text] [Related]
12. An evaluation of polatuzumab vedotin for the treatment of patients with diffuse large B-cell lymphoma.
Walji M; Assouline S
Expert Rev Hematol; 2020 Sep; 13(9):933-942. PubMed ID: 32700586
[TBL] [Abstract][Full Text] [Related]
13. Polatuzumab vedotin-based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience.
Wang YW; Tsai XC; Hou HA; Tien FM; Liu JH; Chou WC; Ko BS; Chen YW; Lin CC; Cheng CL; Lo MY; Lin YC; Lu LC; Wu SJ; Kuo SH; Hong RL; Huang TC; Yao M
Ann Hematol; 2022 Feb; 101(2):349-358. PubMed ID: 34766217
[TBL] [Abstract][Full Text] [Related]
14. [Autologous stem cell transplantation after pola-BR regimen as a salvage therapy in relapsed diffuse large B-cell lymphoma].
Matsuda K; Fujioka Y; Okuda S; Sugimoto K
Rinsho Ketsueki; 2023; 64(3):214-217. PubMed ID: 37019676
[TBL] [Abstract][Full Text] [Related]
15. Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey.
Dal MS; Ulu BU; Uzay A; Akay OM; Beşışık S; Yenerel MN; Çelik S; Kaynar L; Yücel OK; Deveci B; Sönmez M; Mehtap Ö; Beköz HS; Sunu C; Salim O; Ulaş T; Kartı S; Altuntaş F; Ferhanoğlu B; Tuğlular TF
Ann Hematol; 2023 Jan; 102(1):133-140. PubMed ID: 36401621
[TBL] [Abstract][Full Text] [Related]
16. US cost-effectiveness of polatuzumab vedotin, bendamustine and rituximab in diffuse large B-cell lymphoma.
Betts KA; Thuresson PO; Felizzi F; Du EX; Dieye I; Li J; Schulz M; Masaquel AS
J Comp Eff Res; 2020 Oct; 9(14):1003-1015. PubMed ID: 33028076
[No Abstract] [Full Text] [Related]
17. Polatuzumab Vedotin: a New Target for B Cell Malignancies.
Choi Y; Diefenbach CS
Curr Hematol Malig Rep; 2020 Apr; 15(2):125-129. PubMed ID: 32172360
[TBL] [Abstract][Full Text] [Related]
18. Polatuzumab vedotin for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma.
Malecek MK; Watkins MP; Bartlett NL
Expert Opin Biol Ther; 2021 Jul; 21(7):831-839. PubMed ID: 32500753
[TBL] [Abstract][Full Text] [Related]
19. The molecular rationale for the combination of polatuzumab vedotin plus rituximab in diffuse large B-cell lymphoma.
Kawasaki N; Nishito Y; Yoshimura Y; Yoshiura S
Br J Haematol; 2022 Oct; 199(2):245-255. PubMed ID: 35764309
[TBL] [Abstract][Full Text] [Related]
20. [Successful polatuzumab vedotin and rituximab therapy for post-CAR-T relapse of diffuse large B-cell lymphoma].
Kushida T; Hirosawa M; Goto M; Seike Y; Kitamura N; Nakanishi T; Tanaka A; Higashi T; Morimoto H; Tsukada J
Rinsho Ketsueki; 2024; 65(3):180-182. PubMed ID: 38569863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]